These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23226267)

  • 1. Immunotherapy of tumors with α2-macroglobulin-antigen complexes pre-formed in vivo.
    Pawaria S; Kropp LE; Binder RJ
    PLoS One; 2012; 7(11):e50365. PubMed ID: 23226267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91.
    Binder RJ; Karimeddini D; Srivastava PK
    J Immunol; 2001 Apr; 166(8):4968-72. PubMed ID: 11290775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity.
    Binder RJ; Kumar SK; Srivastava PK
    Cancer Immun; 2002 Dec; 2():16. PubMed ID: 12747761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages.
    Tobian AA; Canaday DH; Boom WH; Harding CV
    J Immunol; 2004 May; 172(9):5277-86. PubMed ID: 15100266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification of alpha2-macroglobulin and the construction of immunogenic alpha2-macroglobulin-peptide complexes for use as cancer vaccines.
    Binder RJ
    Methods; 2004 Jan; 32(1):29-31. PubMed ID: 14624874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD91: a receptor for heat shock protein gp96.
    Binder RJ; Han DK; Srivastava PK
    Nat Immunol; 2000 Aug; 1(2):151-5. PubMed ID: 11248808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides.
    Berwin B; Hart JP; Pizzo SV; Nicchitta CV
    J Immunol; 2002 May; 168(9):4282-6. PubMed ID: 11970968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules.
    Matsutake T; Sawamura T; Srivastava PK
    Cancer Immun; 2010 Aug; 10():7. PubMed ID: 20672796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role of CD91 in re-presentation of gp96-chaperoned peptides.
    Binder RJ; Srivastava PK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(16):6128-33. PubMed ID: 15073331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.
    Basu S; Binder RJ; Ramalingam T; Srivastava PK
    Immunity; 2001 Mar; 14(3):303-13. PubMed ID: 11290339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells.
    Tobian AA; Canaday DH; Harding CV
    J Immunol; 2004 Oct; 173(8):5130-7. PubMed ID: 15470057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity.
    Blachere NE; Li Z; Chandawarkar RY; Suto R; Jaikaria NS; Basu S; Udono H; Srivastava PK
    J Exp Med; 1997 Oct; 186(8):1315-22. PubMed ID: 9334371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD91-positive subset of CD11c+ blood dendritic cells: characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens.
    Hart JP; Gunn MD; Pizzo SV
    J Immunol; 2004 Jan; 172(1):70-8. PubMed ID: 14688311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
    van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
    Front Immunol; 2018; 9():1997. PubMed ID: 30237798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo.
    Messmer MN; Pasmowitz J; Kropp LE; Watkins SC; Binder RJ
    J Immunol; 2013 Oct; 191(8):4456-65. PubMed ID: 24048898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
    Galili U; Wigglesworth K; Abdel-Motal UM
    J Immunol; 2007 Apr; 178(7):4676-87. PubMed ID: 17372027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-examination of CD91 function in GRP94 (glycoprotein 96) surface binding, uptake, and peptide cross-presentation.
    Jockheck-Clark AR; Bowers EV; Totonchy MB; Neubauer J; Pizzo SV; Nicchitta CV
    J Immunol; 2010 Dec; 185(11):6819-30. PubMed ID: 21048103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.